Neurocrine(NBIX) Prnewswire·2025-03-17 12:30Core Insights - Neurocrine Biosciences presented data from the KINECT®-HD study demonstrating significant improvements in chorea symptoms in adults with Huntington's disease using once-daily INGREZZA® (valbenazine) capsules [1][6][8] Study Findings - The KINECT-HD study was a Phase 3, randomized, double-blind, placebo-controlled trial involving 128 adults aged 18 to 75 diagnosed with motor-manifest Huntington's disease [4][5] - The primary efficacy endpoint was the Unified Huntington's Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score, which showed a placebo-adjusted mean reduction of 3.2 units (P<0.0001) after 12 weeks of treatment [5][7] - Statistically significant improvements in chorea severity were observed in both upper and lower extremities, with P<0.05 for each region [7] Patient Impact - The analysis indicated that more participants experienced meaningful improvements in chorea, with TMC score shifts from ≥2 at baseline to ≤1 at maintenance with INGREZZA compared to placebo [7] - The most significant improvements were noted in the arms and legs, which were the most severely affected at baseline [2][3] Safety Profile - Treatment-emergent adverse events were consistent with the known safety profile of valbenazine, with common adverse reactions including somnolence, sedation, urticaria, rash, and insomnia [8][20] - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating chorea associated with Huntington's disease and tardive dyskinesia [9][10] Company Overview - Neurocrine Biosciences is focused on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a portfolio that includes FDA-approved therapies for various conditions [22][24]